Revelation Biosciences hires Avance Clinical as CRO for TITAN Phase 2/3
Revelation Biosciences (REVB) selects Avance Clinical as the CRO for its Phase 2/3 TITAN study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.